Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia

Abstract : The optimal management of malignant haematological disorders depend on the degree of tumor load reduction after therapy. Chronic myeloid leukemia constitutes a clinical model for molecular detection and therapy surveillance of malignant disease since this entity was the first leukemia shown to be associated with a specific bcr-abl fusion gene in the patient's leukemia cells. Molecular monitoring of bcr-abl transcript levels by real-time quantitative PCR is increasingly used to assess treatment response in patients with chronic myeloid leukemia (CML). This has become particulary relevant in the era of imatinib therapy when residual levels of leukaemia usually fall below the level of detection by bone marrow cytogenetic analysis. We monitored bcr-abl transcript levels by quantitative real time PCR in 50 tunisian patients treated with imatinib for chronic myeloid leukemia in chronic phase for a median of 29 months (3-60) after they started imatinib. (C) 2008 Elsevier Masson SAS. All rights reserved.
Type de document :
Article dans une revue
Pathologie Biologie, Elsevier Masson, 2009, 57 (5), pp.388-391. 〈10.1016/j.patbio.2007.12.010〉
Liste complète des métadonnées

https://hal-riip.archives-ouvertes.fr/pasteur-01375194
Contributeur : Institut Pasteur Tunis <>
Soumis le : mardi 6 décembre 2016 - 14:29:08
Dernière modification le : lundi 5 février 2018 - 15:22:12

Identifiants

Collections

Citation

S. Menif, S. Zarrouki, R. Jeddi, N. Alaya, Z. Belhadj Ali, et al.. Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia. Pathologie Biologie, Elsevier Masson, 2009, 57 (5), pp.388-391. 〈10.1016/j.patbio.2007.12.010〉. 〈pasteur-01375194〉

Partager

Métriques

Consultations de la notice

32